Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) and contributed to the development of precision medicine. Osimertinib is a standard first-line (1L) treatment for EGFR-mutated NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Taisuke, Kanda, Shintaro, Komatsu, Masamichi, Sonehara, Kei, Tateishi, Kazunari, Takada, Munetake, Kato, Akane, Yamamoto, Manabu, Nishie, Kenichi, Hama, Mineyuki, Agatsuma, Toshihiko, Kakizaki, Yumiko, Yoshiike, Fumiaki, Matsuo, Akemi, Chiaki, Tomoshige, Samizo, Kanae, Takagi, Yoshiko, Yamaura, Maki, Hanaoka, Masayuki, Koizumi, Tomonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326772/
https://www.ncbi.nlm.nih.gov/pubmed/37425417
http://dx.doi.org/10.21037/tlcr-23-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326772/
https://www.ncbi.nlm.nih.gov/pubmed/37425417
http://dx.doi.org/10.21037/tlcr-23-12

Ejemplares similares